Indian markets extended their winning streak for the third straight session, with heavyweight banking names providing the thrust. Fresh business updates from HDFC Bank and YES Bank revealed robust credit expansion that goes beyond routine quarterly prints and points to underlying economic traction in both retail and commercial segments.

HDFC Bank, the largest private lender, clocked gross advances of Rs 30.61 lakh crore for the April-June quarter of FY27, marking a 15.4% year-on-year rise. The print stands out as one of the strongest since the merger integration phase, reflecting steady traction in key lending verticals. The stock had carried governance overhang earlier in the year, but recent leadership realignments and consistent execution appear to be easing investor concerns. Full financial results are due around mid-July, where margin trajectory and asset quality commentary will be closely watched. The advance growth suggests credit demand remains supportive amid a stabilising macro environment.

YES Bank delivered an even sharper expansion, with loans and advances rising 18.4% year-on-year to Rs 2.85 lakh crore. Deposits grew 14% to Rs 3.15 lakh crore while liquidity metrics stayed comfortable. The private lender has been methodically rebuilding its franchise after past challenges, and this consistent credit momentum indicates the turnaround is gaining durability. The board also cleared plans for significant capital raise, providing further headroom for growth. Such prints from two systemically important private banks reinforce the view that lending appetite is returning across segments.

In the power space, Vedanta Power posted a standout operational performance with power sales jumping 38% year-on-year to 5,225 million units in the first quarter. The surge was driven by higher generation at the Meenakshi Energy asset and steady output from Talwandi Sabo. The update arrives shortly after the June demerger and listing of multiple Vedanta entities. Separate listed verticals allow sharper focus and potentially better capital allocation. Early operational delivery in the power business offers initial validation of the restructuring thesis, especially as India’s long-term energy demand trajectory remains intact.

Waaree Energies received a clean regulatory signal from SEBI. The markets regulator exempted the promoter family trust from the mandatory open offer requirement for an internal succession-related transfer of promoter stakes (44.88% direct and 18.34% indirect). The move facilitates a smooth generational transition without any change in management control or public shareholding. For a leading solar player riding India’s renewable capacity addition wave, governance clarity and continued promoter skin-in-the-game remove a potential overhang and support long-term investor comfort.

Sun Pharma secured an important legal shield when the Delhi High Court restrained Finecure Pharmaceuticals from manufacturing or selling drugs under names deceptively similar to its established “Pantocid” brand. The interim injunction protects a key gastro-intestinal product that contributes meaningfully to revenues. In the competitive pharmaceutical landscape, defending brand equity and intellectual property remains critical even for established players. The relief reduces near-term risk of erosion in a high-volume therapy area.

Taken together, these updates reflect different facets of corporate execution in a recovering domestic cycle. Banking majors are expanding books at a healthy clip after a period of caution, energy assets are demonstrating operational leverage post-restructuring, and knowledge businesses are actively safeguarding competitive moats. The broader market has responded positively, with Nifty breaking out of its recent consolidation range and heavyweights like HDFC Bank contributing to the sentiment.

For investors, the developments underscore the importance of tracking execution quality rather than just headline growth. Credit expansion in private banks can act as a leading indicator of economic activity, while regulatory and legal outcomes in renewables and pharma often have multi-quarter implications for valuations. As the Q1 earnings season gathers pace, these specific stories offer concrete reference points to assess which companies are converting macro tailwinds into durable competitive advantages.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Stock markets are subject to volatility and risks. Past performance is not indicative of future results. Readers should conduct their own due diligence or consult a SEBI-registered financial advisor before making any investment decisions. Data is based on publicly available information as of July 6, 2026.